Myeloid-derived suppressor cells (MDSCs) are major contributors to immunosuppression and therapeutic resistance in cancer, yet robust human-relevant platforms for evaluating their function and trafficking remain limited. Here, we established a THP-1–derived MDSC-like cell model and integrated it with a colorectal cancer (CRC) organoid–stromal microenvironment assay. MDSC-like cells were generated under cytokine-driven differentiation conditions and validated by flow cytometry and qRT–PCR. Their immunosuppressive activity was assessed using PBMC/T-cell clustering assays, and their migratory behavior was quantified using a Matrigel-coated transwell system containing CRC organoids and/or cancer-associated fibroblasts (CAFs). This platform enabled parallel assessment of MDSC phenotype, suppressive function, infiltration, and drug response, supporting the preclinical evaluation of MDSC-targeting strategies in a human-relevant setting.
Wookyeom Yang1, Yoon-Ha Go1, Phuong Lan Nguyen1, Dong-Uk Lim1, Boeun Lee2, Kyung Jin Lee2
1 ORGANOIDSCIENCES Ltd., Republic of Korea
2 Lambda Biologics GmbH, Germany
Session Title: Late-Breaking Research: Immunolog 2
Session Start: 4/20/2026 9:00:00 AM
Session End: 4/20/2026 12:00:00 PM
Location: Poster Section 53
Poster Board Number: 18
Abstract Presentation Number: LB153
This poster details a comprehensive methodology for evaluating the complex interactions between immune-suppressive cells and the tumor stroma:
from Apr 19-22, 2026, at the AACR Annual Meeting, San Diego, California, USA
Visit Lambda Biologics at the AACR 2026, Booth 1603 from Apr 17-22 to discuss how our oncology-focused organoid platform helps establishing a sophisticated testing ground for next-generation immuno-oncology candidates and Antibody-Drug Conjugates (ADCs).
To access the full copy of this resource, kindly fill in the following information